Skip to content

Cash ratio at other companies

ALN
Alnylam PharmaceuticalsALNY
1.3×+0.3×
Septerna, Inc. logo
Septerna, Inc.SEPN
0.9×-18.8×
Regenxbio logo
RegenxbioRGNX
0.2×-1.0×
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
1.9×+1.1×
Opko Health logo
Opko HealthOPK
0.2×-0.3×
Ginkgo Bioworks logo
Ginkgo BioworksDNA
2.4×-0.7×

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Calculated from Tectonic Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's cash ratio?
Tectonic Therapeutics (TECX) reported cash ratio of 18.3× in Q1 2026.
How has Tectonic Therapeutics's cash ratio changed year-over-year?
Tectonic Therapeutics's cash ratio decreased by 19.5% year-over-year, from 22.7× to 18.3×.
What is the long-term trend for Tectonic Therapeutics's cash ratio?
Over 5 years (2020 to 2025), Tectonic Therapeutics's cash ratio has grown at a 10.9% compound annual growth rate (CAGR), from 15.6× to 26.3×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.